case_images: PMC8278452_01
case_images: Comparison of chest CT scans before and after treatment, bilateral pleural and interlobar pleural thickening with pleural effusion (arrow).
case_images: 10.1177_11795549211028571-fig1.jpg
case_images: PMC8278452_01_10.1177_11795549211028571-fig1.jpg
case_images: fig1-11795549211028571
case_images: The CT scan showed (Figure 1) bilateral pleural thickening with bilateral pleural effusion, which were consistent with pleural malignant tumor.
case_images: Changes in serum tumor markers (CYFRA 21-1 reference: 0-3.3 ng/ml; NSE reference: 0-16.3 ng/ml; CA125 reference: 0-35 U/ml; CEA reference: 0-5.2 ng/ml; CA724 reference: 0-6.9 U/ml; Ferritin reference: 24-336 ng/ml).
case_images: 10.1177_11795549211028571-fig2.jpg
case_images: PMC8278452_01_10.1177_11795549211028571-fig2.jpg
case_images: fig2-11795549211028571
case_images: The patient had obvious dyspnea, cough, expectoration, and laboratory tests (Table 1) (Figure 2) showed platelet aggregation, hypoproteinemia, and abnormal coagulation function.
case_images: Histopathological examination results of cervical lymph nodes. (a, b) Hematoxylin and eosin-stained shows squamous cell carcinoma with neuroendocrine function. (c, d) Tumor cells staining positive for p40. (c) 200x, (d) 400x, (e) Tumor cells staining positive for p63.
case_images: 10.1177_11795549211028571-fig3.jpg
case_images: PMC8278452_01_10.1177_11795549211028571-fig3.jpg
case_images: fig3-11795549211028571
case_images: The immunohistochemical results supported the neuroendocrine function of squamous cell carcinoma (Figure 3): Ki67 (+, 70%), CD56 (-), Syn (++), P40 (+++), P63 (++), CD20 (-), Vim (-), EMA (++), TTF1 (++), NaspinA (-), CD99 (-), and PD-L1 (+, 80%).
case_images: Treatment timeline of the patient.
case_images: 10.1177_11795549211028571-fig4.jpg
case_images: PMC8278452_01_10.1177_11795549211028571-fig4.jpg
case_images: fig4-11795549211028571
case_images: Fortunately, the tumor had a high expression of PD-L1; thus, we decided to administer camrelizumab according to the recommended intravenous dose of 200 mg (once every 3 weeks) for a total of six times from October 20, 2019 to February 11, 2020 (Figure 4).